The city of Detroit, Michigan, currently has 50 active clinical trials seeking participants for Lymphoma research studies.
Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors
NCT05225584
Recruiting
This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of KT-333 in Adult patients with Relapsed or Refractory (R/R) Lymphomas, Large Granular Lymphocytic Leukemia (LGL-L), T-cell prolymphocytic leukemia (T-PLL), and Solid Tumors. The Phase 1a stage of the study will explore escalating doses of single-agent KT-333. The Phase Ib stage will consist of 4 expansion cohorts to further characterize the safety, tolerability and the pharmacokineti... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: Henry Ford Hospital, Detroit, Michigan
Conditions: Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), Solid Tumors, T-cell Prolymphocytic Leukemia (T-PLL)
Register for Updates
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma
NCT05569057
Recruiting
This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/03/2022
Locations: Henry Ford Health, Detroit, Michigan
Conditions: Advanced Solid Tumor, Cutaneous T-cell Lymphoma (CTCL)
Register for Updates